Kazia Therapeutics Shares outstanding
What is the Shares outstanding of Kazia Therapeutics?
The Shares outstanding of Kazia Therapeutics Limited is 132.037M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with shares outstanding similar to Kazia Therapeutics
- Flir Systems has Shares outstanding of 131.932M
- Skyharbour Resources has Shares outstanding of 131.954M
- Jubilant FoodWorks has Shares outstanding of 131.969M
- Jubilant FoodWorks has Shares outstanding of 131.969M
- Shanghai Jiaoda Withub Information Industrial has Shares outstanding of 132.000M
- Upwork Inc has Shares outstanding of 132.007M
- Kazia Therapeutics has Shares outstanding of 132.037M
- Vulcan Materials has Shares outstanding of 132.048M
- Vulcan Materials Co has Shares outstanding of 132.060M
- Covia has Shares outstanding of 132.098M
- REA has Shares outstanding of 132.117M
- Albion Technology & General VCT Plc has Shares outstanding of 132.131M
- Outcrop Gold has Shares outstanding of 132.149M